Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $4.6 million.

  • Theravance Biopharma's Share-based Compensation fell 779.77% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year decrease of 733.92%. This contributed to the annual value of $21.4 million for FY2024, which is 1567.93% down from last year.
  • Per Theravance Biopharma's latest filing, its Share-based Compensation stood at $4.6 million for Q3 2025, which was down 779.77% from $4.5 million recorded in Q2 2025.
  • Theravance Biopharma's Share-based Compensation's 5-year high stood at $16.9 million during Q4 2021, with a 5-year trough of $4.5 million in Q2 2025.
  • In the last 5 years, Theravance Biopharma's Share-based Compensation had a median value of $6.3 million in 2023 and averaged $8.6 million.
  • Per our database at Business Quant, Theravance Biopharma's Share-based Compensation soared by 879.04% in 2021 and then crashed by 5891.95% in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's Share-based Compensation stood at $16.9 million in 2021, then plummeted by 58.92% to $7.0 million in 2022, then decreased by 16.2% to $5.8 million in 2023, then increased by 0.03% to $5.8 million in 2024, then dropped by 21.46% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $4.5 million for Q2 2025, and $4.9 million during Q1 2025.